PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jrsocmedLink to Publisher's site
 
J R Soc Med. 1992 November; 85(11): 692–698.
PMCID: PMC1293730

Tissue plasminogen activator for thrombolytic therapy: expectation versus reality.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.4M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bachmann F, Kruithof IE. Tissue plasminogen activator: chemical and physiological aspects. Semin Thromb Hemost. 1984 Jan;10(1):6–17. [PubMed]
  • Collen D, Lijnen HR. Tissue-type plasminogen activator. Mechanisms of action and thrombolytic properties. Haemostasis. 1986;16 (Suppl 3):25–32. [PubMed]
  • Camiolo SM, Thorsen S, Astrup T. Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin. Proc Soc Exp Biol Med. 1971 Oct;138(1):277–280. [PubMed]
  • Collen D, Stassen JM, Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. J Clin Invest. 1983 Feb;71(2):368–376. [PMC free article] [PubMed]
  • Urano T, Sator de Serrano V, Gaffney PJ, Castellino FJ. Effectors of the activation of human [Glu1]plasminogen by human tissue plasminogen activator. Biochemistry. 1988 Aug 23;27(17):6522–6528. [PubMed]
  • Gaffney PJ, Urano T, de Serrano VS, Mahmoud-Alexandroni M, Metzger AR, Castellino FJ. Roles for chloride ion and fibrinogen in the activation of [Glu1]plasminogen in human plasma. Proc Natl Acad Sci U S A. 1988 May;85(10):3595–3598. [PubMed]
  • Gaffney PJ, Brasher M, Lord K, Strachan CJ, Wilkinson AR, Kakkar VV, Scully MF. Fibrin subunits in venous and arterial thromboembolism. Cardiovasc Res. 1976 Jul;10(4):421–426. [PubMed]
  • Van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KA, de Geest H, Verstraete M, Collen D, Sobel BE. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med. 1984 Mar 8;310(10):609–613. [PubMed]
  • Verstraete M, Bleifeld W, Brower RW, Charbonnier B, Collen D, de Bono DP, Dunning AJ, Lennane RJ, Lubsen J, Mathey DG, et al. Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet. 1985 Nov 2;2(8462):965–969. [PubMed]
  • Goldhaber SZ, Kessler CM, Heit J, Markis J, Sharma GV, Dawley D, Nagel JS, Meyerovitz M, Kim D, Vaughan DE, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet. 1988 Aug 6;2(8606):293–298. [PubMed]
  • Marder VJ, Sherry S. Thrombolytic therapy: current status (2). N Engl J Med. 1988 Jun 16;318(24):1585–1595. [PubMed]
  • Verstraete M, Bernard R, Bory M, Brower RW, Collen D, de Bono DP, Erbel R, Huhmann W, Lennane RJ, Lubsen J, et al. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet. 1985 Apr 13;1(8433):842–847. [PubMed]
  • Van de Werf F, Arnold AE. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. BMJ. 1988 Nov 26;297(6660):1374–1379. [PMC free article] [PubMed]
  • Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet. 1988 Sep 3;2(8610):525–530. [PubMed]
  • Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood. 1991 Dec 15;78(12):3114–3124. [PubMed]
  • Nelles L, Lijnen HR, Collen D, Holmes WE. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator. J Biol Chem. 1987 Aug 5;262(22):10855–10862. [PubMed]
  • Piérard L, Jacobs P, Gheysen D, Hoylaerts M, André B, Topisirovic L, Cravador A, de Foresta F, Herzog A, Collen D, et al. Mutant and chimeric recombinant plasminogen activators. Production in eukaryotic cells and preliminary characterization. J Biol Chem. 1987 Aug 25;262(24):11771–11778. [PubMed]
  • Gheysen D, Lijnen HR, Piérard L, de Foresta F, Demarsin E, Jacobs P, De Wilde M, Bollen A, Collen D. Characterization of a recombinant fusion protein of the finger domain of tissue-type plasminogen activator with a truncated single chain urokinase-type plasminogen activator. J Biol Chem. 1987 Aug 25;262(24):11779–11784. [PubMed]
  • Lijnen HR, Nelles L, Van Hoef B, Demarsin E, Collen D. Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator. J Biol Chem. 1988 Dec 15;263(35):19083–19091. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press